- Company
- Bridge plans to establish follow-up development of BBT-877
- by Chon, Seung-Hyun Nov 20, 2020 06:11am
- Bridge Biotherapeutics announced on the 17th that it will establish a follow-up development and business strategy for BBT-877, which was recently returned from Boehringer Ingelheim, within the first half of next year. Bridge Biotherapeutics introduced research and development strategies at an online IR briefing for investors on this day. B
- Policy
- The government is negotiating with Moderna & Pfizer
- by Kim, Jung-Ju Nov 20, 2020 06:11am
- The quarantine authorities plan to promote COVID-19 vaccine prior to next year's flu vaccination. In addition, it is said that negotiations are underway to purchase COVID-19 vaccines by Moderna and Pfizer, which showed excellent effects on prevention. Kwon Jun-wook, deputy chief at the Central Disease Control Headquarters, revealed the cur
- Company
- Zejula for ovarian cancer gets close to 4th-line coverage
- by Eo, Yun-Ho Nov 19, 2020 06:14am
- An anticancer therapy for ovarian cancer Zejula is at the last threshold to win the reimbursement expansion. According to pharmaceutical industry sources, Takeda Pharmaceutical has recently initiated the drug pricing negotiation with the National Health Insurance Service (NHIS) on a poly ADP-ribose polymerase (PPARP) inhibitor Zejula’s
- Company
- SGLT-2 inhibitor, effective for patients with kidney disease
- by Nov 19, 2020 06:10am
- SGLT-2 inhibitors, developed as a treatment for diabetes, are further expanding their indications. It has proven its protective effect beyond simple cardiovascular safety, and recently, data proving the benefit of kidney disease is accumulating. In patients with type 2 diabetes, SGLT-2 inhibitors prevented the deterioration of renal function,
- Company
- Game changer Spravato first novel antidepressant in 30 years
- by Nov 19, 2020 06:10am
- For the first time in three decades, a novel antidepressant has been released in South Korea. Although the drug would be able to provide new treatment opportunity to patients with severe depression through a new mechanism of action, the patients may face high barrier in convenience and pricing. On Nov. 17, Janssen Korea convened a press
- Company
- Reorganization of multinational companies & plans
- by Nov 19, 2020 06:10am
- A meeting is held to discuss ways to improve workers' environment related to reorganization of multinational pharmaceutical companies. Yoon Joonbyeong, a member of the National Assembly's Environment and Labor Committee, announced that the meeting will be held on the 18th at 10:00 am in the 2nd conference room of the Seoul Metropolitan Counci
- Policy
- Clinical re-evaluation is being reviewed for Formoterol
- by Lee, Tak-Sun Nov 19, 2020 06:10am
- The MFDS is reviewing a clinical re-evaluation of Formoterol Fumarate Hydrate tablets and syrups used to treat asthma. This is because the need for validation was raised during the renewal review process. However, the policy is to finalize the re-evaluation through the Central Pharmaceutical Affairs Review Committee. According to the MF
- Company
- Sanofi to stand alone Consumer Healthcare and offer ERP
- by Nov 18, 2020 12:19pm
- Sanofi is reportedly planning to spin off the Consumer Healthcare (CHC) businesses and offer early retirement program (ERP) to employees under CHC and General Medicine (GenMed). On Nov. 13, Sanofi-Aventis Korea notified all employees the global Sanofi CHC stand alone plan that would also affect the South Korean branch as well. Sanofi
- Policy
- The use of antibiotics in Korea is 1.6 X that of the OECD
- by Kim, Jung-Ju Nov 18, 2020 07:59am
- The use of antibiotics in Korea was 1.6 times the average of OECD member countries in 2018. Of these, inadequate prescriptions such as antibiotics for colds account for 28%, so it is important to prevent resistance. The KDCA (Director Jeong Eun-kyeong) emphasized the adherence and practice of antibiotic resistance prevention rules to over
- Company
- All bets are off for patent dispute of Galvus
- by Kim, Jin-Gu Nov 18, 2020 06:36am
- The patent dispute over the DPP-4 inhibitor-based diabetes treatment'Galvus (Vildagliptin)' turns around and ends at the KIPO. The Patent Court of Korea sided with Novartis, and Ahn-gook, who lost, gave up the Supreme Court appeal, and the KIPO finally took over the case again. According to the pharmaceutical industry on the 17th, Ahn-
